• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Montes Archimedes Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/25/21 9:06:41 AM ET
    $MAAC
    Business Services
    Finance
    Get the next $MAAC alert in real time by email
    8-K 1 tm2119232d5_8k.htm FORM 8-K

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 25, 2021

     

    MONTES ARCHIMEDES ACQUISITION CORP.
    (Exact name of registrant as specified in its charter)

     

    Delaware 001-39597 85-1830874
    (State or other jurisdiction of
    incorporation or organization)
    (Commission File Number) (I.R.S. Employer
    Identification Number)

     

    724 Oak Grove Ave., Suite 130
    Menlo Park, CA
    94025
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (650) 384-6558

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ýWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Units, each consisting of one share of Class A common stock, $0.0001 par value, and one-half of one warrant  MAACU  The Nasdaq Stock Market LLC
           
    Shares of Class A common stock included as part of the units  MAAC  The Nasdaq Stock Market LLC
           
    Warrants included as part of the units, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50  MAACW  The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company  x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure.

     

    Attached as Exhibit 99.1 hereto and incorporated into this Item 7.01 by reference is the Analyst Day presentation that Roivant Sciences Ltd. (“Roivant”) has prepared for use in connection with its Analyst Days, scheduled for June 25 and June 29, 2021 relating to the proposed business combination of Roivant and Montes Archimedes Acquisition Corp. (“MAAC”). The foregoing is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

     

    Forward Looking Statements

     

    This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans as they relate to the proposed business combination, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although each of MAAC and Roivant believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of MAAC and Roivant caution you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, risks and uncertainties are described in the Registration Statement relating to the proposed business combination filed by Roivant with the SEC and other documents filed by MAAC or Roivant from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements in this communication include, but are not limited to, statements regarding the proposed business combination, including the timing and structure of the transaction, the proceeds of the transaction and the benefits of the transaction. Neither MAAC nor Roivant can assure you that the forward-looking statements in this communication will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to complete the proposed business combination due to the failure to obtain approval from MAAC’s stockholders or satisfy other closing conditions in the definitive agreement relating to the proposed business combination (the “Business Combination Agreement”), the occurrence of any event that could give rise to the termination of the Business Combination Agreement, the ability to recognize the anticipated benefits of the proposed business combination, the amount of redemption requests made by MAAC’s public stockholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the proposed business combination, the outcome of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those included under the heading “Risk Factors” in the Registration Statement filed by Roivant with the SEC and those included under the heading “Risk Factors” in the annual report on Form 10-K for year ended December 31, 2020 of MAAC (as amended) and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by MAAC, Roivant, their respective directors, officers or employees or any other person that MAAC and Roivant will achieve their objectives and plans in any specified time frame, or at all. The forward-looking statements in this communication represent the views of MAAC and Roivant, as applicable, as of the date of this communication. Subsequent events and developments may cause that view to change. However, while MAAC and Roivant may elect to update these forward-looking statements at some point in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of MAAC or Roivant as of any date subsequent to the date of this communication.

     

    1

     

     

    Disclaimer

     

    This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the above-referenced business combination and does not constitute an offer to sell or a solicitation of an offer to buy any securities of MAAC or Roivant, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
        Description
    99.1     Analyst Day Presentation

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

     

    Dated: June 25, 2021    
         
      MONTES ARCHIMEDES ACQUISITION CORP.
         
      By: /s/ Maria C. Walker
        Name:  Maria C. Walker
        Title: Chief Financial Officer

     

    3

     

    Get the next $MAAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MAAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MAAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Patient Square Capital Llc

    4 - Montes Archimedes Acquisition Corp (0001819263) (Issuer)

    10/4/21 5:20:05 PM ET
    $MAAC
    Business Services
    Finance

    SEC Form 4 filed by Walker Maria C

    4 - Montes Archimedes Acquisition Corp (0001819263) (Issuer)

    10/4/21 5:13:55 PM ET
    $MAAC
    Business Services
    Finance

    SEC Form 4 filed by Oesterle Stephen N.

    4 - Montes Archimedes Acquisition Corp (0001819263) (Issuer)

    10/4/21 5:13:42 PM ET
    $MAAC
    Business Services
    Finance

    $MAAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing

    Roivant will begin trading on Nasdaq under the ticker "ROIV" later todayR&D Day presentations from September 28th highlighting Roivant's pipeline and discovery platform available on Roivant's investor page BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it has closed its business combination with Montes Archimedes Acquisition Corp. (NASDAQ:MAAC), a special purpose acquisition company, as well as a concurrent PIPE financing. Outstanding shares and warrants of MAAC have been exchanged for newly issued Roivant shares and w

    10/1/21 8:00:00 AM ET
    $MAAC
    Business Services
    Finance

    Roivant Provides Corporate Updates

    NEW YORK and BASEL, Switzerland, June 9, 2021 /PRNewswire/ -- Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health, the leader in clinical data exchange, have signed a definitive merger agreement. The combined entity, to be named Datavant, will be the nation's largest health data ecosystem, enabling patients, providers, payers, health data analytics companies, patient-facing applications, government agencies, and life science companies to securely exchange their patient-level data. The combined company will have an enterprise value of $7 billion. The merger is subject to typical regulatory approvals and is

    6/9/21 7:40:00 AM ET
    $MAAC
    Business Services
    Finance

    Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology

    NEW YORK, MENLO PARK, Calif., LONDON, and BASEL, Switzerland, May 3, 2021 /PRNewswire/ -- Roivant Sciences, a biopharmaceutical and healthcare technology company, and Montes Archimedes Acquisition Corp. (NASDAQ:MAAC), a special purpose acquisition company sponsored by Patient Square Capital, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, outstanding shares and warrants of MAAC will be exchanged for newly issued shares and warrants of Roivant Sciences, which is expected to be listed on Nasdaq under the new ticker symbol "ROIV." The transaction is expected to deliver up to $611 million of gross proceeds to fund discover

    5/3/21 7:00:00 AM ET
    $MAAC
    Business Services
    Finance

    $MAAC
    SEC Filings

    View All

    SEC Form 15-12B filed by Montes Archimedes Acquisition Corp.

    15-12B - Montes Archimedes Acquisition Corp (0001819263) (Filer)

    10/12/21 8:30:50 AM ET
    $MAAC
    Business Services
    Finance

    SEC Form 25-NSE filed by Montes Archimedes Acquisition Corp.

    25-NSE - Montes Archimedes Acquisition Corp (0001819263) (Subject)

    9/30/21 4:11:17 PM ET
    $MAAC
    Business Services
    Finance

    Montes Archimedes Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - Montes Archimedes Acquisition Corp (0001819263) (Filer)

    9/29/21 7:58:17 AM ET
    $MAAC
    Business Services
    Finance

    $MAAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Montes Archimedes Acquisition Corp. (Amendment)

    SC 13G/A - Montes Archimedes Acquisition Corp (0001819263) (Subject)

    10/12/21 11:51:38 AM ET
    $MAAC
    Business Services
    Finance

    SEC Form SC 13G filed by Montes Archimedes Acquisition Corp.

    SC 13G - Montes Archimedes Acquisition Corp (0001819263) (Subject)

    9/27/21 5:14:37 PM ET
    $MAAC
    Business Services
    Finance

    SEC Form SC 13G filed

    SC 13G - Montes Archimedes Acquisition Corp (0001819263) (Subject)

    2/26/21 5:15:27 PM ET
    $MAAC
    Business Services
    Finance